The majority of antibiotics for medical, veterinary and agricultural applications are derived from secondary metabolites produced by the Streptomyces bacteria. However, the huge number of antimicrobial compounds these bacteria currently supply is likely to be only the tip of the iceberg. Much remains unknown about their metabolic pathways. ADP-ribosylation (addition of ADP linked to the sugar ribose) is widely conserved in viruses, bacteria and eukaryotes. It is important in numerous cellular processes and has been linked to antibiotic resistance in bacteria. Following the trail of ADP-ribosylation pathways in Streptomyces, STREPUNLOCKED plans to unlock the potential of these bacteria to deliver novel and effective therapeutics that combat the perfidious and increasing emergence of multi-drug resistant microorganisms.